Egis Gyogyszergyar

Other

Egyt Gyogyszervegyeszeti Gyar

Egis Gyogyszergyar Rt.

Egis Gyogyszergvar

Egis Cyogyszergvar

Janos Egri

Karoly Magyar

Pal Fekete

Ferenc Simon

Gyula Sebestyen

Istvan Simonyi

Denes Bezzegh

Attila Nagy

Laszlo Puskas

Marta Kovacs

Margit Nagy Nee Kricsfalussy

Janos Varga

Hedvig Szauder Nee Lauko

Marton Fekete

Attila Mandi

Frigyes Gorgenyi

Pal Vago

Jozsef Kelemen

Erzsebet Barczay

Lajos Fekete

Katalin Zukovics Nee Sumeg

Maria Szeli

Sandor Erdos

Rita Balazs

Istvan Seres

Antal Mosonyi

Attila Romvary

Katalin Zukovics Nae Someg

Gizelle Miholics

Katalin Zukovics

Olga Magyar

Katalin Sumeg

Maria Szeli Nee Seger

Maria Hoor

Gyoorgy Kucsera

Gabor Zalai

A pharmaceutical ointment is disclosed containing to 10 percent by mass of micronized piroxicam, 15 to 30 percent by mass of hydrophobic carrier(s), 60 to 75 percent by mass of water, 0.1 to 10 percent by mass of additive(s), and 2 to 5 percent by mass of emulsifiers selected from (i) a poly(ethylene glycol) alkyl or alkenyl ether and (ii) a sorbitane ester of a fatty acid or an oleic acid in a mass ratio of 3:1 to 1:3. The ointment is free from skin irritative action and has local antiphlogistic activity. In addition, a process for preparing he pharmaceutical ointment is provided.

Pharmaceutical ointment being free from skin irritative action and a

The invention relates to a process for the preparation of solid pharmaceutical compositions. More specifically, the invention relates to a process for the preparation of tablets ensuring an increased active ingredient release, where said tablets comprise as active ingredient a mixture of L-3,4-dihydroxyphenylalanine and L-alpha-hydrazino-alpha-methyl-3,4-dihydroxyphenyl propionic acid in a (3-12):1 mass to mass ratio, which comprises admixing any of L-3,4-dihydroxyphenylalanine and L-alpha-hydrazino-alpha-methyl-3,4-dihydroxyphenyl propionic acid, or both of them, with a hydrophilic diluent, preferably lactose and/or microcrystalline cellulose, and optionally with a colouring agent, blending the mixture thus obtained with auxiliary agents conventionally used for the preparation of tablets and optionally with the other active ingredient, furthermore with a solution of stearin in an appropriate solvent, preferably an alkanol comprising 2 to 4 carbon atoms, drying and granulating the mixture thus obtained, optionally admixing further auxiliary agent(s) to the dry granulate, compressing it into tablets comprising 50 to 70% by mass of active ingredient and, if desired, applying a film-coating onto the surface of the tablets thus obtained. The process according to the invention provides tablets of appropriate quality with rapid active ingredient release.

Process for the preparation of solid pharmaceutical compositions

The invention relates to novel pyroxycam solutions of increased stability and without tissue-damaging effect, particularly to solutions which can be used as injectable solutions or eye drops. The solution according to the invention comprises 1 to 5% by mass of 4 hydroxy- 2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide, 0.5 to 5.0 % by mass of sodium glycinecarboxylate as well as 0.5 to 12% by mass of additive(s). The invention further relates to a process for the preparation of the above solutions.

Drug solutions of increased stability and without tissue-damaging effect

The invention relates to synergistically active veterinary compositions useful particularly for the treatment of mastitis and metritis. The invention further relates to a process for preparing these compositions. The compositions according to the invention comprise, based on 1 part by weight of 6,9,18-tris(2-aminoethyl) -15-benzyl-21-[.sup.- 2,8-bis(2-aminoethyl)-5-(1-hydroxyethyl) -15-methyl-4,7,10-trioxo-3,6,9-triazaheptadecanamido]-3-(1-hydroxyethyl)-1 2-isobutyl-1,4,7,10,13,16,19-heptaazacyclotricosane-2, 5,8,11,14,17,20-heptaone or a pharmaceutically acceptable acid addition salt thereof, 1 to 1000 parts by weight of 1-(2-chlorophenyl)-diphenylmethyl-1H-imidazole or 1 to 400 parts by weight of 2-methyl-5,7-dichloro-8-hydroxyquinoline, respectively, optionally in admixture with carriers and/or additives commonly used in the pharmaceutical industry.

Synergistically active veterinary compositions and process for preparing

The invention relates to weight gain-increasing compositions, particularly fodder supplement, premix, drinking water supplement, bolus and/or microcapsule containing 0.001 to 90% by weight of 1-(3,5-dihydroxyphenyl)-2-(tertiary butylamino)-ethanol or a physiologically acceptable acid addition salt thereof as active ingredient in admixture with inert solid and/or liquid carrier(s).

Method for weight gain-increasing of fodder utilization of pigs, cattle

The invention refers to a novel pharmaceutical composition having especially antimycotic activity and comprising the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline of formula (I) ##STR1## and one or more pharmaceutically acceptable carriers. The pharmaceutical composition of the invention can be used for the effective treatment of mycotic infections on the skin surface, mucous membranes or nails. The complex of formula (I) is prepared by reacting a solution of an alkali metal salt of 5-chloro-7-iodo-8-hydroxyquinoline with a solution containing an excess of an inorganic or organic zinc salt or a zinc complex having a lower stability constant than that of the complex of formula (I) and separating the product precipitated.

Pharmaceutical composition comprising an organic zinc complex and a

The invention relates to a synergistic veterinary composition and/or a fodder premix useful for preventing or curing bacterial, fungal and protozoic infection particularly occurring at poultry species. Furthermore the invention relates to a process for preparing same. The composition or premix contains 1 to 100 parts by mass of 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine and/or 1 to 100 parts by mass of 2,4-diamino-5-(3,4-dimethoxybenzyl)pyrimidine as well as 1 to 100 parts by mass of 2,6-dimethoxy-4-sulfanilamidopyrimidine or a pharmaceutically acceptable salt thereof and 1 to 100 parts by mass of 8-hydroxyquinoline or a pharmaceutically acceptable acid addition salt thereof optionally in admixture with carrier(s) and/or additive(s) commonly used in the pharmaceutical industry or for the preparation of premixes.

Synergistic veterinary composition and/or fodder premix and process for

The invention refers to a powder mixture having a high propylene glycol content and a process for the preparation thereof. The powder mixture consists of 25 to 75 percent by weight of propylene glycol and 75 to 25 percent by weight of magnesium oxide and/or magnesium peroxide and/or magnesium carbonate as a solid carrier(s). The powder mixture can be treated as a solid powder and it does not deliquesce in the air even when stored for a long time. The mixture can be used as solid propylene glycol in dietetic products for calf, piglet and lamb, in pharmaceutical compositions for the treatment of ketosis and in other pharmaceutical compositions for veterinary use.

Powder mixture having high propylene glycol content and process for the

A reversible electric drive with bidirectional back-current brakes fed by a rectifier supplied from a pair of A.C. power lines for a D.C. motor having two directions of rotation and two poles, comprises a control rectifier bridge for each direction of rotation, each bridge having two branches each containing a diode which is common to both bridges, a shunt resistor for each direction of rotation which is identical with a braking resistor for each other direction of rotation connected in series with the motor for each bridge, each bridge having two other branches each containing a rectifier thyristor with cathodes of each rectifier thyristor connected to a common point. The common point of each bridge is connected to one of the poles of the motor with a control thyristor connected to each common point in series with each respective shunt resistor of each bridge and connected to each other by a connecting point. The common diode is connected to the connecting point, and a braking thyristor is provided between a connecting point of each braking thyristor is provided between a connecting point of each shunt resistor and its respective control thyristor and the common points respectively.

Reversible electric drive with bidirectional back-current brake and fed

Growing community of inventors

Budapest, Hungary

Janos Egri